Pfizer (PFE) Gets a Hold Rating from Barclays

In a report issued on July 28, Carter Gould from Barclays maintained a Hold rating on Pfizer (PFEResearch Report), with a price target of $41.00. The company’s shares closed last Thursday at $42.79, close to its 52-week high of $43.74.

According to TipRanks.com, Gould is a 3-star analyst with an average return of 5.2% and a 44.9% success rate. Gould covers the Healthcare sector, focusing on stocks such as Reata Pharmaceuticals, Travere Therapeutics, and Eli Lilly & Co.

The word on The Street in general, suggests a Hold analyst consensus rating for Pfizer with a $44.36 average price target, implying a 2.6% upside from current levels. In a report released yesterday, Mizuho Securities also maintained a Hold rating on the stock with a $43.00 price target.

See today’s analyst top recommended stocks >>

Pfizer’s market cap is currently $243.2B and has a P/E ratio of 21.40. The company has a Price to Book ratio of -25.77.

Based on the recent corporate insider activity of 39 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PFE in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Pfizer Inc. develops, manufactures and sells healthcare products, including innovative medicines and vaccines. Its key focus areas include oncology, inflammation & immunology, rare disease, vaccines and internal medicine. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Read More on PFE: